Skip to Content

Viatris Inc - Stock Quote VTRS

Rating as of

Morningstar's Viatris Inc Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Viatris Reports Solid First-Quarter Results; Biosimilar Divestiture on Track for Second Half of 2022

Dylan Finley, CFA Equity Analyst

Analyst Note

| Dylan Finley, CFA |

Viatris' first-quarter results were largely within our expectations, with mid-single-digit revenue erosion across branded and generic drug categories partially offset by the realization of post-Upjohn merger cost synergies. Overall, there were few surprises during the quarter, and management reiterated its top- and bottom-line guidance targets for the year. We are maintaining our fair value estimate of $12.50 per share.

Read Full Analysis

Viatris Inc's Company Profile

Business Description

Formed by the combination of Mylan and Pfizer’s Upjohn business in 2020, Viatris is one of the world’s largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company’s branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

1000 Mylan Boulevard
Canonsburg, PA, 15317
T +1 724 514-1800
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Mar 31, 2022
Fiscal Year End Dec 31, 2022
Stock Type High Yield
Employees 37,000

Viatris Inc's Related Articles & News